keyword
MENU ▼
Read by QxMD icon Read
search

Eye anti-VEGF

keyword
https://www.readbyqxmd.com/read/29772041/endophthalmitis-associated-with-intravitreal-injections-of-anti-vegf-agents-at-a-tertiary-referral-center-in-house-and-referred-cases
#1
Nicolas A Yannuzzi, Ninel Z Gregori, Philip J Rosenfeld, Nidhi Relhan, Nimesh A Patel, Nancy Si, Darlene Miller, Sander R Dubovy, William E Smiddy, Stephen G Schwartz, Harry W Flynn
BACKGROUND AND OBJECTIVE: To report the incidence rates, causative organisms, and visual acuity (VA) outcomes in patients with endophthalmitis associated with intravitreal injection of anti-vascular endothelial growth factor inhibitors. PATIENTS AND METHODS: Retrospective case series between 2005 and 2017. RESULTS: The study included 39 eyes of 39 patients, including 27 (69%) referred and 12 (31%) institutional patients. The use of topical antibiotics after an injection was gradually phased out at the authors' institution, where the preinjection rate of all clinically suspected endophthalmitis was 0...
May 1, 2018: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/29771880/-anti-vegf-therapy-for-diabetic-macular-edema-from-theory-to-clinical-practice
#2
A Zh Fursova, N V Chubar, M S Tarasov, I F Niculich, M A Vasilyeva, O G Gusarevich
PURPOSE: To evaluate clinical effectiveness of aflibercept therapy for patients with diabetic macular edema (DME) - both naïve to the drug and unresponsive to previous anti-VEGF treatment. MATERIAL AND METHODS: The study included 127 patients (127 eyes) divided into two groups. The first group consisted of 100 primary DME patients (100 eyes) with mean age of 68.48±2.56 years and average disease duration of 12.50±7.85 years. The second group comprised 27 patients (27 eyes) with resistant macular edema who had received three or more 0...
2018: Vestnik Oftalmologii
https://www.readbyqxmd.com/read/29768269/long-term-results-of-combination-treatment-with-single-dose-ranibizumab-plus-photodynamic-therapy-for-retinal-angiomatous-proliferation
#3
Panagiotis Malamos, Ioannis Tservakis, Menelaos Kanakis, Chrysoula Koutsiouki, Evita Kiskira, Georgios Mylonas, John Lakoumentas, Ilias Georgalas
PURPOSE: To present functional and anatomic outcomes of combination therapy with ranibizumab and photodynamic therapy (PDT) in a series of retinal angiomatous proliferation (RAP) cases. METHODS: A total of 17 eyes of 17 patients with RAP were included. Thirteen eyes were treatment naïve and 4 were already on ranibizumab monotherapy. Combined treatment with single-dose ranibizumab and PDT was performed on all treatment-naïve cases. Follow-up was performed every month for 6-38 months, using optical coherence tomography and indocyanine green angiography when necessary...
May 16, 2018: Ophthalmologica. Journal International D'ophtalmologie
https://www.readbyqxmd.com/read/29768266/subfoveal-choroidal-thickness-in-eyes-with-neovascular-age-related-macular-degeneration-treated-with-anti-vascular-endothelial-growth-factor-agents
#4
Tereza Cristina Moreira Kanadani, Carlos Eduardo Veloso, Márcio B Nehemy
PURPOSE: We aimed to assess the subfoveal choroidal thickness (SFChT) and the effect of treatment with anti-vascular endothelial growth factor (anti-VEGF) agents on the SFChT in age-related macular degeneration (AMD) subtypes. METHODS: We enrolled 128 eyes of 107 patients with neovascular AMD (60 women; 47 men; mean age, 73.6 ± 8.9 years), and prospectively evaluated the best-corrected visual acuity (BCVA) and SFChT at baseline and at 3, 6, and 12 months after treatment with anti-VEGF agents...
May 16, 2018: Ophthalmologica. Journal International D'ophtalmologie
https://www.readbyqxmd.com/read/29765959/outcome-of-5-year-treatment-of-neovascular-age-related-macular-degeneration-with-intravitreal-anti-vegf-using-treat-and-extend-regimen
#5
Polona Jaki Mekjavic, Polona Zaletel Benda
Objective: The aim of this study is twofold. First , to evaluate the long-term outcome of anti-vascular endothelial growth factor (anti-VEGF) treatment in a clinical setting using the "treat-and-extend regimen" (TER) in patients with neovascular age-related macular degeneration (nAMD). Second , to determine the proportion of patients treated with anti-VEGF with good visual acuity (VA), i.e., vision sufficient to maintain a high level of independence. Design: We conducted a single center retrospective review of patients with treatment-naive nAMD who were treated with anti-VEGF...
2018: Frontiers in Medicine
https://www.readbyqxmd.com/read/29739007/optical-coherence-tomography-angiography-to-quantify-choroidal-neovascularization-in-response-to-aflibercept
#6
Jun Takeuchi, Keiko Kataoka, Yasuki Ito, Kei Takayama, Tetsuhiro Yasuma, Hiroki Kaneko, Hiroko Terasaki
PURPOSE: To investigate the microvascular changes in choroidal<X00_Del_Blind>0</X00_Del_Blind> neovascularization (CNV) using optical coherence tomography angiography (OCTA) during anti-vascular endothelial growth factor (VEGF) therapies. METHODS: We retrospectively collected data on consecutive treatment-naïve eyes with typical age-related macular degeneration that initially received 3 aflibercept injections. OCTA was performed at baseline and at 1, 2, and 4 months of follow-up...
May 8, 2018: Ophthalmologica. Journal International D'ophtalmologie
https://www.readbyqxmd.com/read/29734180/influence-of-the-vitreoretinal-interface-on-the-treatment-with-anti-vegf-for-exudative-age-related-macular-degeneration
#7
Pedro Gil, João Gil, Nuno Oliveira, Inês Laíns, Eduardo Nery Rossi Camilo, Cristina Fonseca, Miguel Raimundo, Maria da Luz Cachulo, Rufino Silva
PURPOSE: To investigate the influence of the vitreoretinal interface on the outcomes of different ranibizumab regimens for exudative age-related macular degeneration. METHODS: We conducted a retrospective subanalysis of 2 prospective clinical trials. Patients were treated with ranibizumab for 12 months according to 3 different regimens: pro-re-nata (PRN), treat and extend (T&amp;E), and monthly. Vitreoretinal interface was assessed for absence (group ON) or presence (group OFF) of posterior vitreous detachment (PVD)...
May 7, 2018: Ophthalmologica. Journal International D'ophtalmologie
https://www.readbyqxmd.com/read/29730822/shall-we-stay-or-shall-we-switch-continued-anti-vegf-therapy-versus-early-switch-to-dexamethasone-implant-in-refractory-diabetic-macular-edema
#8
Catharina Busch, Dinah Zur, Samantha Fraser-Bell, Inês Laíns, Ana Rita Santos, Marco Lupidi, Carlo Cagini, Pierre-Henry Gabrielle, Aude Couturier, Valérie Mané-Tauty, Ermete Giancipoli, Giuseppe D'Amico Ricci, Zafer Cebeci, Patricio J Rodríguez-Valdés, Voraporn Chaikitmongkol, Atchara Amphornphruet, Isaac Hindi, Kushal Agrawal, Jay Chhablani, Anat Loewenstein, Matias Iglicki, Matus Rehak
AIMS: To compare functional and anatomical outcomes of continued anti-vascular endothelial growth factor (VEGF) therapy versus dexamethasone (DEX) implant in eyes with refractory diabetic macular edema (DME) after three initial anti-VEGF injections in a real-world setting. METHODS: To be included in this retrospective multicenter, case-control study, eyes were required: (1) to present with early refractory DME, as defined by visual acuity (VA) gain ≤ 5 letters or reduction in central subfield thickness (CST) ≤ 20%, after a loading phase of anti-VEGF therapy (three monthly injections) and (2) to treat further with (a) anti-VEGF therapy or (b) DEX implant...
May 5, 2018: Acta Diabetologica
https://www.readbyqxmd.com/read/29719645/intravitreal-injection-of-anti-vascular-endothelial-growth-factor-agents-for-ocular-vascular-diseases-clinical-practice-guideline
#9
Homayoun Nikkhah, Saeed Karimi, Hamid Ahmadieh, Mohsen Azarmina, Majid Abrishami, Hossein Ahoor, Yousef Alizadeh, Hasan Behboudi, Narsis Daftarian, Mohammad Hossein Dehghan, Morteza Entezari, Fereydoun Farrahi, Heshmatollah Ghanbari, Khalil Ghasemi Falavarjani, Mohammad Ali Javadi, Reza Karkhaneh, Siamak Moradian, Masoud Reza Manaviat, Morsal Mehryar, Ramin Nourinia, Mohammad Mehdi Parvaresh, Alireza Ramezani, Alireza Ragati Haghi, Mohammad Riazi-Esfahani, Masoud Soheilian, Mohsen Shahsavari, Hossein-Ali Shahriari, Zhale Rajavi, Sare Safi, Armin Shirvani, Saeed Rahmani, Hamideh Sabbaghi, Mojgan Pakbin, Bahareh Kheiri, Hossein Ziaei
Purpose: To provide the clinical recommendations for the administration of intravitreal anti-vascular endothelial growth factor (VEGF) drugs especially bavacizumab for ocular vascular diseases including diabetic macular edema, neovascular age-related macular degeneration, myopic choroidal neovascularization, retinal vein occlusion and central serous chorioretinopathy. Methods: Twenty clinical questions were developed by the guideline technical committee. Relevant websites and databases were searched to find out the pertinent clinical practice guidelines to answer the questions...
April 2018: Journal of Ophthalmic & Vision Research
https://www.readbyqxmd.com/read/29709424/preclinical-pharmacokinetics-of-a-recombinant-humanized-rabbit-anti-vegf-monoclonal-antibody-in-rabbits-and-monkeys
#10
Dong-An Yu, Meng You, Wan-Wan Ji, You Lu, Bin Liu, Shou-Sheng Yan
TMAB001 is a humanized rabbit monoclonal antibody (mAb) designed to bind and neutralize human vascular endothelial growth factor (VEGF)-165. The purpose of the study was to investigate the pharmacokinetics (PK) and ocular tissue distribution after a single intravitreal (IVT) dose in rabbits and monkeys. Rabbits (2.5 mg/eye; n = 40) and monkeys (2.5 mg/eye; n = 12) received TMAB001 as a bilateral IVT dose. TMAB001 concentrations were measured in ocular tissues in all rabbits and monkeys by enzyme-linked immunosorbent assay (ELISA)...
April 27, 2018: Toxicology Letters
https://www.readbyqxmd.com/read/29697591/optimal-management-of-pigment-epithelial-detachments-in-eyes-with-neovascular-age-related-macular-degeneration
#11
Arshad M Khanani, David Eichenbaum, Patricio G Schlottmann, Lisa Tuomi, David Sarraf
PURPOSE: This review aimed to determine the optimal management of retinal pigment epithelial detachments (PEDs) in neovascular age-related macular degeneration (nAMD) based on review of available evidence in the literature. METHODS: A comprehensive literature review evaluates previous retrospective and prospective studies that assessed the treatment of PEDs in nAMD. RESULTS: Studies illustrated that anti-vascular endothelial growth factor (VEGF) therapy can be effective in eyes with PED secondary to nAMD...
April 24, 2018: Retina
https://www.readbyqxmd.com/read/29687595/the-area-of-fixation-covaries-with-short-term-changes-in-visual-acuity-after-anti-vascular-endothelial-growth-factor-treatment-in-patients-with-diabetic-macular-oedema
#12
Nanna Staehr Jakobsen, Dorte Ancher Larsen, Toke Bek
PURPOSE: Diabetic maculopathy can be treated with intravitreal injection of vascular endothelial growth factor (VEGF) inhibitors. However, the therapy is not effective in all patients, and it would be desirable to have parameters for differentiating patients who will benefit from treatment from those who will not. Retinal fixation has been shown to be impaired in patients with low visual acuity (VA) secondary to macular disease, but the changes in fixational eye movements after anti-VEGF treatment for diabetic maculopathy have not been investigated...
April 24, 2018: Acta Ophthalmologica
https://www.readbyqxmd.com/read/29684329/vision-outcomes-following-anti-vascular-endothelial-growth-factor-treatment-of-diabetic-macular-edema-in-clinical-practice
#13
Nancy M Holekamp, Joanna Campbell, Arghavan Almony, Herbert Ingraham, Steven Marks, Hitesh Chandwani, Ashley L Cole, Szilárd Kiss
PURPOSE: To determine monitoring and treatment patterns, and vision outcomes in real-world patients initiating anti-vascular endothelial growth factor (anti-VEGF) therapy for diabetic macular edema (DME). DESIGN: Retrospective interventional cohort study. METHODS: SETTING: Electronic medical record analysis of Geisinger Health System data. STUDY POPULATION: 110 patients (121 study eyes) initiating intravitreal ranibizumab or bevacizumab for DME during January 2007‒May 2012, with baseline corrected visual acuity of 20/40‒20/320, and ≥1 ophthalmologist visits during follow-up...
April 20, 2018: American Journal of Ophthalmology
https://www.readbyqxmd.com/read/29682153/antioxidant-and-anti-inflammatory-effects-of-blueberry-anthocyanins-on-high-glucose-induced-human-retinal-capillary-endothelial-cells
#14
Wuyang Huang, Zheng Yan, Dajing Li, Yanhong Ma, Jianzhong Zhou, Zhongquan Sui
Blueberries possess abundant anthocyanins, which benefit eye health. The purpose of this study was to explore the protective functional role of blueberry anthocyanin extract (BAE) and its predominant constituents, malvidin (Mv), malvidin-3-glucoside (Mv-3-glc), and malvidin-3-galactoside (Mv-3-gal), on high glucose- (HG-) induced injury in human retinal capillary endothelial cells (HRCECs). The results showed that BAE, Mv, Mv-3-glc, and Mv-3-gal enhanced cell viability ( P < 0.05 versus the HG group at 24 h); decreased the reactive oxygen species (ROS, P < 0...
2018: Oxidative Medicine and Cellular Longevity
https://www.readbyqxmd.com/read/29681832/one-year-outcome-of-aflibercept-and-photodynamic-therapy-in-a-caucasian-patient-with-polypoidal-choroidal-vasculopathy-refractory-to-ranibizumab-and-photodynamic-therapy
#15
Marta Medina-Baena, María Jesús Huertos-Carrillo, Laura Rodríguez, Juan Ignacio García-Pulido, Carlos Cornejo-Castillo, José María Calandria-Amiguetti
Polypoidal choroidal vasculopathy (PCV) is a subtype of neovascular age-related macular degeneration characterised by an abnormal branching vascular network with aneurysmal polypoidal choroidal vascular lesions. PCV is more prevalent in Asian populations than in Caucasians, which may explain its underdiagnosis in Western countries. Evidence regarding the efficacy of different anti-vascular endothelial growth factor (anti-VEGF) agents on PCV is scarce, with most of these studies being conducted in Asian treatment-naïve patients...
January 2018: Case Reports in Ophthalmology
https://www.readbyqxmd.com/read/29678729/statins-reduce-testicular-and-ocular-vegf-a-potential-compromise-to-microcirculation
#16
Nuran Ekerbiçer, Tugba Gurpinar, Ali Riza Sisman, Guven Guvendi, Ulas M Camsari, Nazan Uysal
Microcirculation has great importance in eye and testicular tissue and is necessary to have adequate and appropriate amount of angiogenesis. It is known that high levels of Vascular Endothelial Growth Factor (VEGF) trigger uncontrolled angiogenesis, whereas inadequate VEGF can lead to decreased tissue perfusion and oxygenation. The aim of this study was to investigate effects of VEGF in testicular and ocular tissues in both non-diabetic and diabetic rats treated by statin. Atorvastatin (10 mg/kg daily given by orally gavage) was administered for two weeks...
April 17, 2018: Microvascular Research
https://www.readbyqxmd.com/read/29677368/in-vivo-characterization-of-spontaneous-retinal-neovascularization-in-the-mouse-eye-by-multifunctional-optical-coherence-tomography
#17
Marco Augustin, Matthias Wechdorn, Ulrike Pfeiffenberger, Tanja Himmel, Stanislava Fialová, René M Werkmeister, Christoph K Hitzenberger, Martin Glösmann, Bernhard Baumann
Purpose: To investigate the early development of spontaneous retinal neovascularization in the murine retina by a multifunctional optical coherence tomography approach. To characterize involved tissue changes in vivo and describe structural and functional changes over time. Methods: A multifunctional optical coherence tomography (OCT) system providing 3-fold contrast comprising reflectivity, polarization sensitivity, and OCT angiography (OCTA) was utilized to image very-low-density lipoprotein receptor (VLDLR) knockout mice...
April 1, 2018: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/29677356/volume-rendered-projection-resolved-oct-angiography-3d-lesion-complexity-is-associated-with-therapy-response-in-wet-age-related-macular-degeneration
#18
Peter L Nesper, Brian T Soetikno, Alison D Treister, Amani A Fawzi
Purpose: To explore whether quantitative three-dimensional (3D) analysis of choroidal neovascularization (CNV) using projection-resolved optical coherence tomography angiography (PR-OCTA) is associated with treatment response in neovascular age-related macular degeneration (nAMD). Methods: Retrospective, cross-sectional study of 51 eyes of 49 patients undergoing individualized anti-VEGF therapy for nAMD. Patients were classified as "good" or "poor" responders, requiring injections at less or more frequently than 6-week intervals, respectively...
April 1, 2018: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/29675384/effect-of-anti-vegf-treatment-on-retinopathy-of-prematurity-in-zone-ii-stage-3
#19
Xiu-Mei Yang, Yue-Xiang Zhao, Zong-Hua Wang, Lu Liu
AIM: To evaluate the effect of intravitreal ranibizumab injection for retinopathy of prematurity (ROP) in Zone II Stage 3+ . METHODS: Data was collected for ROP patients with Zone II Stage 3+ who received intravitreal ranibizumab injections between October 2014 and Janu-ary 2017 at the Department of Ophthalmology in our hospital. No prior laser or other intravitreal treatment was done. Prior to the intervention and at each follow-up visit, fundus examination was performed...
2018: International Journal of Ophthalmology
https://www.readbyqxmd.com/read/29675373/comparison-of-the-effects-of-intravitreal-bevacizumab-and-dexamethasone-in-experimental-posterior-penetrating-eye-injury
#20
Ayse Oner, Nisa Kahraman, Saim Ozdamar, Esra Balcioglu
AIM: To compare the effects of intravitreal anti-vascular endothelial growth factor (VEGF) and dexamethasone in an experimental rabbit model of posterior penetrating ocular injury. METHODS: Thirty white New Zealand rabbits were included in the study. A posterior penetrating ocular injury was performed at the superotemporal quadrant. They were randomly divided into three groups. The rabbits in group 1 received intravitreal dexamethasone, in group 2 they received intravitreal bevacizumab and those in group 3 received intravitreal physiological saline solution in both eyes...
2018: International Journal of Ophthalmology
keyword
keyword
36614
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"